Range of qualified clients: CDEC talked over the uncertainty in the volume of clients with moderately extreme to serious hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical gurus consulted by CADTH indicated that some people who are labeled as possessing mild or reasonable disease can have a significant bleeding phenotype, whic